Breakthrough T1D™
Formerly JDRF

Stage 2 T1D
Disease Modifying Therapy Clinical Trials (Multi-site)

DRUG	**A Study of Baricitinib for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (BARICADE-DELAY)** AGES 1-36 STAGE 2 T1D (AT LEAST 2 AUTOANTIBODIES) ORAL PILL **NOT YET RECRUITING**	

Stage 2 T1D
Disease Modifying Therapy Clinical Trials (Single site)

DRUG	**GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab (GLP-TEP)** AGES 12-50 STAGE 2 T1D (AT LEAST 2 AUTOANTIBODIES) ORAL PILL VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE,TN	

Stage 3 T1D
Disease Modifying Therapy Clinical Trials (Multi-site)

DRUG	**A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)** AGES 1-36 WITHIN 8 WEEKS OF DIAGNOSIS ORAL PILL **NOT YET RECRUITING**	

Breakthrough T1D™
Formerly JDRF

DRUG	**A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes (βETA PRESERVE)** AGES 1-25 WITHIN 8 WEEKS OF DIAGNOSIS IV INFUSION	
DRUG	**TArgeting Type 1 Diabetes Using POLyamines (TADPOL)** AGES 4-40 WITHIN 100 DAYS OF DIAGNOSIS ORAL PILL	
DRUG	**Precision Administration of Anti-thymocyte Globulin With or Without Verapamil** AGES 6-36 WITHIN 100 DAYS OF DIAGNOSIS IV INFUSIONS AND ORAL PILL	
DRUG	**Rezpegaldesleukin in New Onset Type 1 Diabetes Mellitus** AGES 8-45 WITHIN 100 DAYS OF DIAGNOSIS INJECTIONS **NOT YET RECRUITING**	

Breakthrough T1D™
Formerly JDRF

DRUG	**A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (WAVE T1D)** AGES 9-21 WITHIN 6 MONTHS OF DIAGNOSIS IV INFUSION **NOT YET RECRUITING**	
DRUG	**CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)** AGES 12-35 DIAGNOSED FOR LESS THAN 6 MONTHS IV INFUSIONS	
DRUG	**A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes (DIAGNODE-3)** AGES 12-28 WITHIN 6 MONTHS OF DIAGNOSIS LYMPH NODE INJECTION	
DRUG	**FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)** AGES 12-35 WITHIN 3 MONTHS OF DIAGNOSIS INFUSION FOLLOWED BY INJECTIONS	

Breakthrough T1D™
Formerly JDRF

DRUG	**Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule (T1D OBTAIN)** AGES 12-35 WITHIN 90 DAYS OF DIAGNOSIS INJECTION	
DRUG	**SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes (SAFEGUARD)** PART A AGES 15-40 PART B AGES 5-40 WITHIN 100 DAYS OF DIAGNOSIS IV INFUSION	
DRUG	**Denosumab for Type 1 Diabetes** FEMALES AGES 18-50 MALES AGES 21-50 DIAGNOSED FOR LESS THAN 6 YEARS INJECTION	
DRUG	**A Study of GNTI-122 in Adults Recently Diagnosed With T1D (POLARIS)** AGES 18-45 WITHIN 120 DAYS OF DIAGNOSIS SINGLE IV INJECTION	

Breakthrough T1D™
Formerly JDRF

Stage 3 Disease Modifying Therapy Clinical Trials (Single site)		
DRUG	**PREBIOTICS IN PATIENTS WITH TYPE 1 DIABETES** AGES 7+ (Lead Site) AGES 7-17 (Subsites) DIAGNOSED FOR LESS THAN 12 MONTHS ORAL PILL University of Calgary	
DRUG	**Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells** AGES 18-40 DIAGNOSED FOR LESS THAN 6 MONTHS INFUSION MEDICAL UNIVERSITY OF SOUTH CAROLINA	
DRUG	**An Adaptive Design of MTX228** AGES 18-65 DIAGNOSED FOR AT LEAST 1 YEAR ORAL PILL UNIVERSITY OF ALBERTA	
DRUG	**MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes** AGES 18-45 DIAGNOSED FOR LESS THAN 2 YEARS INJECTION UNIVERSITY OF COLORADO, DENVER	

Breakthrough T1D™
Formerly JDRF

Trial Tools & Contact Information

 TRIAL TOOLS	**Clinical Trials Connection Tool** Match to a clinical trial in 60 seconds	
 CONTACT INFO	**Clinical Trial Education Volunteers** Your key to participation! Connect with a local volunteer trained to answer any questions you may have.	